文献速递甲状腺疾病

BRAFV600E突变型未分化甲状腺癌新辅助达拉非尼联合曲美替尼后完全手术切除

Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib in BRAFV600E-Mutated Anaplastic Thyroid Carcinoma.
PubMed 文献 · Thyroid · 2019-01-01

本病例系列纳入2017年1月至2018年2月诊断的6例BRAFV600E突变型未分化甲状腺癌(ATC)患者,先给予达拉非尼联合曲美替尼(DT)新辅助治疗,随后手术切除并辅助放化疗。全部患者实现完全手术切除,病理缓解率高,6个月和1年总生存率分别为100%和83%,局部区域控制率100%。

要点

  • DT新辅助治疗使初始不可切除的BRAFV600E突变ATC实现完全切除。
  • 病理显示ATC活力显著降低并残留乳头状癌成分,病理缓解率高。
  • 6个月和1年总生存率分别为100%和83%,局部区域控制率100%。

核心结论

  • DT新辅助治疗后手术切除在BRAFV600E突变型局部晚期ATC中可行,可实现完全切除、减少气管切开需求并获得持久局部区域控制。

研究设计与样本

  • 病例系列研究,纳入2017年1月至2018年2月诊断的6例连续BRAFV600E突变型ATC患者。
  • 治疗前经病理确诊ATC,BRAFV600E状态通过免疫组化或循环肿瘤DNA测序确定。
  • 所有患者接受达拉非尼联合曲美替尼后手术切除并辅助放化疗,其中3例还接受帕博利珠单抗。

主要发现

  • 全部6例患者实现完全手术切除。
  • 切除标本病理分析显示高病理缓解率,ATC活力显著降低并残留乳头状甲状腺癌成分。
  • 6个月和1年总生存率分别为100%和83%,局部区域控制率为100%。
  • 2例患者分别于诊断后8个月和14个月死于远处转移,无局部区域病变证据;其余4例末次随访无疾病证据。

临床怎么用

  • 对初始不可切除的BRAFV600E突变型ATC,可考虑DT新辅助治疗后再评估手术切除。
  • 该方案可能减少气管切开需求并改善症状。

局限性

  • 样本量小(6例),为病例系列研究,证据级别有限。
  • 部分患者同时接受帕博利珠单抗,联合方案贡献难以区分。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: When achieved, complete surgical resection improves outcomes in anaplastic thyroid carcinoma (ATC). However, most ATC patients present with advanced inoperable disease, often with impending airway obstruction, increased hemorrhage risk, and significant dysphagia. Novel treatment strategies are critically needed to improve disease control and decrease locoregional morbidity. The objective of this study was to determine the feasibility and effectiveness of a neoadjuvant regimen by using dabrafenib with trametinib followed by surgical resection in patients with initially unresectable BRAFV600E-mutated ATC. Methods: Case series of six consecutive patients with BRAFV600E-mutated ATC diagnosed between January 2017 and February 2018. Pathologic confirmation of ATC was obtained before treatment. BRAFV600E status was ascertained via immunohistochemistry or sequencing of circulating tumor DNA. All patients received dabrafenib and trametinib (DT) followed by surgical resection and adjuvant chemoradiation. Three patients also received pembrolizumab. Results: Complete surgical resection was achieved in all patients. Histopathologic analyses of resected specimens showed high pathologic response rates with significantly decreased ATC viability and residual papillary thyroid carcinoma components. Overall survival at six months and one year was 100% and 83%, respectively. Locoregional control rate was 100%. Two patients died of distant metastases without evidence of locoregional disease at 8 and 14 months from diagnosis. The remaining four patients had no evidence of disease at the last follow-up. Conclusions: We report the first series in the literature of BRAFV600E-mutated ATC patients with locoregionally advanced disease treated with DT followed by surgical resection. We demonstrated feasibility of complete resection, decreased need for tracheostomy, high pathologic response rates, and durable locoregional control with symptom amelioration.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Wang JR, Zafereo ME, Dadu R, et al. Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib in BRAFV600E-Mutated Anaplastic Thyroid Carcinoma. Thyroid. 2019. PMID: 31319771. doi:10.1089/thy.2019.0133

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。